The FDA's new guidance
The guidance published on Tuesday targets a fast-growing field: mobile apps that drugmakers provide with prescription medicines, from dose reminders to symptom tracking and patient coaching.
According to the FDA, the document helps both drug manufacturers and technology developers understand their obligations, rather than having to guess in what has been a murky regulatory area.
Key points of the guidance
The FDA document sets out several specific principles:
- Apps linked to medical devices, such as software paired with an asthma inhaler, should generally be included in the associated drug's label.
- Standalone apps that track symptoms, provide reminders or offer coaching should be listed in the label only if essential for safe and effective use or if they offer meaningful clinical benefit.
- The guidance specifies when app content must be submitted to the FDA and what information companies need to provide.
This classification clearly distinguishes between apps that are an integral part of a therapy and those that are merely supporting tools.
















